Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Rheincell logo — Catalent manufactures 70 billion doses and supports over 7,0...

Rheincell

Catalent manufactures 70 billion doses and supports over 7,000 products for 1,000 customers globally.

Founded 2017 Germany Langenfeld, Germany 11-50 employees Biopharma, Biotechnology +1

General Information

Company Name Rheincell
Founded Year 2017
Location Germany Langenfeld, Germany
Employees 11-50
Industries Biopharma, Biotechnology, Manufacturing
Social

Get notified when Rheincell moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Rheincell

Rheincell is a Germany-based startup that operates in the biopharma, biotechnology, and manufacturing industries. Founded in 2017, the company's slogan "Catalent manufactures 70 billion doses and supports over 7,000 products for 1,000 customers globally" highlights its dedication to serving a wide customer base. Catalent, a publicly traded company since 2014, has a significant global presence with approximately 19,000+ employees collaborating with over 1,000 customers worldwide. The company's focus on introducing 200 new products annually and producing over 70 billion doses demonstrates its commitment to innovation and scale. As the global leader in empowering pharma, biotech, and consumer health partners, Catalent is positioned as a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Although specific details about the last investment and investors are not available, Rheincell's strong market positioning and focus on patient-centric solutions make it an intriguing prospect for potential investors seeking opportunities in the biopharma and biotechnology sectors.

Taxonomy: pharmaceutical manufacturing, global supply chain, drug manufacturing, biotech industry, biopharmaceuticals, patient-centric, personalized medicines, S&P 500 company, innovation, employee collaboration, consumer health, publicly traded company, life-cycle supply

No funding data available for Rheincell yet.

Get notified when Rheincell raises funding

Rheincell Alternatives & Competitors

Rheincell vs
Catalent
Catalent United States

more products. better treatments. reliably supplied. ™

Post Ipo Debt
12614 employees
Biotechnology, Manufacturing
Rheincell vs
Catalent
Catalent United States

Catalent is a leading provider of advanced drug delivery technologies, development, and manufacturin...

12547 employees
Rheincell vs
Viamedi Healthcare GmbH
Viamedi Healthcare GmbH

Viamedi Healthcare GmbH is your partner for quality, reliability, and sustainability.

8 employees
Logistics, Manufacturing

FAQ About Rheincell

Catalent manufactures 70 billion doses and supports over 7,000 products for 1,000 customers globally.
Rheincell was founded in 2017.
Rheincell is headquartered in Langenfeld, Germany.
Rheincell operates in the following industries: Biopharma, Biotechnology, Manufacturing.
Rheincell has approximately 11-50 employees.
Top alternatives and competitors to Rheincell include Catalent, Catalent, Viamedi Healthcare GmbH, AMW GmbH, Cambridge Cognition. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rheincell and Catalent are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Rheincell and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes